Side Effect Management
Patients With COVID-19 Treated for Cancer at Risk for Thromboembolisms
January 18th 2024Patients recently treated for cancer who required hospitalization for COVID-19 were at risk for venous thromboembolisms (VTEs), recent research has found, with investigators determining that patients who experience a thromboembolic event (TEE) are at a 20% to 25% risk of death.
Weekly Fosaprepitant Betters Quality of Life During Chemoradiotherapy
August 2nd 2023Patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy reported higher quality of life and were less likely to experience vomiting when receiving fosaprepitant every week as opposed to every three weeks.